mHealth Intervention for Schizophrenia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Schizophrenia+1 More
mHealth Intervention - Other
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will use smartphone technology to help prescribing medication for people with FEP. Data on symptoms and functioning will be collected in real-time to help make decisions on what will work best.

Eligible Conditions
  • Schizophrenia
  • polytetrafluoroethylene

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Schizophrenia

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: baseline to 6 months

baseline to 6 months
change of Client Satisfaction Questionnaire (CSQ-8) from baseline to 6 months
change of Treatment Satisfaction Questionnaire for Medication (TQSM) from baseline to 6 months

Trial Safety

Safety Progress

1 of 3

Other trials for Schizophrenia

Trial Design

2 Treatment Groups

Treatment as Usual group
1 of 2
mHealth intervention group
1 of 2
Active Control
Experimental Treatment

23 Total Participants · 2 Treatment Groups

Primary Treatment: mHealth Intervention · No Placebo Group · N/A

mHealth intervention group
Other
Experimental Group · 1 Intervention: mHealth Intervention · Intervention Types: Other
Treatment as Usual groupNoIntervention Group · 1 Intervention: Treatment as Usual group · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 6 months

Who is running the clinical trial?

New York State Psychiatric Institute, Washington Heights Community ServiceUNKNOWN
Northwell Health, Early Treatment Program at Lenox HillUNKNOWN
Bestself Behavioral Health, Inc.UNKNOWN
The Institute for Family Health Center for Counseling at WaltonUNKNOWN
New York State Psychiatric InstituteLead Sponsor
455 Previous Clinical Trials
148,552 Total Patients Enrolled
30 Trials studying Schizophrenia
85,554 Patients Enrolled for Schizophrenia
Scott Stroup, MD, MPHPrincipal Investigator - New York State Psychiatric Institute
New York State Psychiatric Institute
2 Previous Clinical Trials
461 Total Patients Enrolled
2 Trials studying Schizophrenia
461 Patients Enrolled for Schizophrenia

Eligibility Criteria

Age < 65 · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The study found that people who participated in OnTrackNY for less than a year were more likely to need medication adjustments and less likely to graduate from the program.
People who are 16 to 30 years old and of any race or ethnicity can participate in OnTrackNY.
Able to understand and willing to sign a consent form, and then participate in the intervention.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: October 14th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.